Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real-life experience

References

• Annese V, Beaugerie L, Egan L, on behalf of ECCO, et al. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohn’s Colitis. 2015;9(11):945–965.
   Google Scholar
• Kim ER, Chang DK. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. WJG. 2014;20(29):9872–9881.
   PubMed Web of Science ®Google Scholar
• Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526–535.
   PubMed Web of Science ®Google Scholar
• Castaño-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-Analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther. 2014;39(7):645–659.
   PubMed Web of Science ®Google Scholar
• Shergill AK, Farraye FA. Toward a consensus on endoscopic surveillance of patients with colonic inflammatory bowel disease. GastrointestEndosc Clin N Am. 2014;24(3):469–481.
   PubMedGoogle Scholar
• Flynn AD, Valentine JF. Chromoendoscopy for dysplasia surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(7):1440–1452.
   PubMed Web of Science ®Google Scholar
• Laine L, Kaltenbach T, Barkun A, et al. SCENIC Guideline Development Panel. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology. 2015;148(3):639–651.
   PubMed Web of Science ®Google Scholar
• Galanopoulos M, Tsoukali E, Gkeros F, et al. Screening and surveillance methods for dysplasia in inflammatory bowel disease patients: where do we stand? WJGE. 2018;10(10):250–258.
   Google Scholar
• Klepp P, Tollisen A, Røseth A, et al. Real-life chromoendoscopy for dysplasia surveillance in ulcerative colitis. WJG. 2018;24(35):4069–4076.
   PubMed Web of Science ®Google Scholar
• Higgins PDR. Editorial: Miles to go on the SCENIC route: should chromoendoscopy become the standard of care in IBD surveillance? Am J Gastroenterol. 2015;110(7):1035–1037.
   PubMed Web of Science ®Google Scholar
• Marion JF, Sands BE. The SCENIC consensus statement on surveillance and management of dysplasia in inflammatory bowel disease: praise and words of caution. Gastroenterology. 2015;148(3):462–467.
   PubMed Web of Science ®Google Scholar
• Endoscopic Classification Review Group. The Paris classification of superficial neoplastic lesions: esophagus, stomach, and colon. GastrointestEndosc. 2003;58(suppl):S3–S43.
   Google Scholar
• Kudo S, Rubino C, Teixeira C, et al. Pit pattern in colorectal neoplasia: endoscopic magnifying view. Endoscopy. 2004;33(04):367–373.
   Google Scholar
• Carballal S, Maisterra S, López-Serrano A, et al. Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD. Gut. 2018;67(1):70–78.
   PubMed Web of Science ®Google Scholar
• Aladren BS, Gonzalez-Lama Y, Garcia-Alvarado M, on behalf of GEICYL (group of inflammatory bowel disease of Castilla y León), et al. Even non-experts identify non-dysplastic lesions in inflammatory bowel disease via chromoendoscopy: results of a screening program in real-life. Endosc Int Open. 2019;07(06):E743–E750.
   Google Scholar
• Thomas T, Abrams KA, Robinson RJ, et al. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment PharmacolTher. 2007;25(6):657–668.
   PubMed Web of Science ®Google Scholar
• Althumairi AA, Lazarev MG, Gearhart SL. Inflammatory bowel disease associated neoplasia: a surgeon's perspective. WJG. 2016;22(3):961–973.
   PubMed Web of Science ®Google Scholar
• Kaltenbach T, Sandborn WJ. Endoscopy in inflammatory bowel disease: advances in dysplasia detection and management. GastrointestEndosc. 2017;86(6):962–971.
   PubMed Web of Science ®Google Scholar
• Yang DH, Kim J, Song EM, et al. Outcomes of ulcerative colitis-associated dysplasia patients referred for potential endoscopic submucosal dissection. J Gastroenterol Hepatol. 2019;34(9):1581–1589.
   PubMed Web of Science ®Google Scholar
• Suzuki N, Toyonaga T, East JE. Endoscopic submucosal dissection of colitis-related dysplasia. Endoscopy. 2017;49(12):1237–1242.
   PubMed Web of Science ®Google Scholar
• Kinoshita S, Uraoka T, Nishizawa T, et al. The role of colorectal endoscopic submucosal dissection in patients with ulcerative colitis. GastrointestEndosc. 2018;87(4):1079–1084.
   PubMed Web of Science ®Google Scholar
• Iannone A, Ruospo M, Palmer SC, et al. Systematic review with network meta-analysis: endoscopic techniques for dysplasia surveillance in inflammatory bowel disease. Aliment Pharmacol Ther. 2019;50(8):858–871.
   PubMed Web of Science ®Google Scholar
• Rutter MD, Saunders BP, Wilkinson KH, et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. GastrointestEndosc. 2004;60(3):334–339.
   PubMed Web of Science ®Google Scholar
• Toruner M, Harewood GC, Loftus EV, et al. Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:428–434.
   PubMed Web of Science ®Google Scholar
• Mooiweer E, van der Meulen-de Jong AE, Ponsioen CY, et al. Chromoendoscopy for surveillance in inflammatory bowel disease does not increase neoplasia detection compared with conventional colonoscopy with random biopsies: results from a large retrospective study. Am J Gastroenterol. 2015;110(7):1014–1021.
   PubMed Web of Science ®Google Scholar
• Cremer A, Demetter P, De Vos M, et al. Risk of development of more-advanced lesions in patients with inflammatory bowel diseases and dysplasia. Clin Gastroenterol Hepatol. 2020;18(7):1528–1536.
   PubMed Web of Science ®Google Scholar
• Carrat F, Seksik P, Colombel JF, the CESAME Study Group, et al. The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(4):533–541.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Fiorino G, Lytras T, et al. Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(9):1179–1192.
   PubMed Web of Science ®Google Scholar
• Gordillo J, Cabré E, Garcia-Planella E, et al. Thiopurine therapy reduces the incidence of colorectal neoplasia in patients with ulcerative colitis. Data from the ENEIDA Registry. ECCOJC. 2015;9(12):1063–1070.
   Google Scholar
• Lu MJ, Qiu XY, Mao XQ, et al. Systematic review with meta-analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease. AlimentPharmacolTher. 2018;47:318–331.
   Web of Science ®Google Scholar
• Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413.
   PubMed Web of Science ®Google Scholar